Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin in Urothelial Carcinoma
NCT03051373Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel and tegafur in transitional cell carcinoma (TCC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Progression-free survival up to 12 months. Started Apr 2017; status: completed.
02
Drugs
paclitaxeltegafur
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT03051373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051373.